File info: application/pdf · 15 pages · 735.69KB
Document preview and download links are below.
Extracted Text
Sidoti Winter 2021 Investor Conference January 13th � 14th, 2021 NASDAQ : BSGM SYMBOL: BSGM 1 Disclaimer This presentation contains forward-looking statements including statements that address activities, events or developments that BioSig expects, believes or anticipates will or may occur in the future, such as predictions of financial performance, approvals and launches by BioSig of new products, market acceptance of BioSig's products, market and procedure projections, financing plans, and related documents. Forward-looking statements are based on BioSig's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond BioSig's control. These risks and uncertainties include the timing of approvals for BioSig products, rate and degree of market acceptance of products, BioSig's ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products and the impact of failure to obtain such clearances and approvals on its ability to promote its products and train doctors and operators in the use of its products, the timing of and ability to obtain reimbursement if required of procedures utilizing BioSig's products and the potential impact of current healthcare reform initiatives thereon, competition from existing and new products and procedures or BioSig's ability to effectively react to other risks and uncertainties described from time to time in BioSig's SEC filings, such as fluctuation of financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government regulation, negative publicity, current worldwide economic conditions and share price volatility. BioSig does not guarantee any forward-looking statements, and actual results may differ materially from those projected. Unless required by law, BioSig undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. SYMBOL: BSGM 2 Who We Are � NASDAQ: BSGM � EP Tech Market 13.5% CAGR � Global EP Market Expected to be $12.2 Billion by 2026* � 31 Patents Issued � First Customer is #1 Center by Volume in U.S. � Razor & Blade Business Model � FDA Approved � Unblinding of clinical data in 2021 Data source: MarketWatch Global Electrophysiology Device Market Could Exceed $12.2 Billion By 2026 SYMBOL: BSGM 3 PURE EPTM Developed Through Collaboration with Leading Centers Relationships at leading, high-volume centers create traction for PURE EPTM in the market 2011 2013 2014 2014 2015 Concept developed with Texas Cardiac Arrhythmia Institute Proof of concept test completed at UCLA Prototype test with UCLA Initial pre-clinical planning at Mayo Clinic First pre-clinical trials at Mayo Clinic 2016 Advanced research at Mayo Clinic, trials at Mount Sinai 2016 Technology development partnership with Minnetronix 2017 Strategic collaboration with Mayo Clinic, first beta units, pre-FDA testing 2018 FDA 510(k) clearance 2019 First patient cases and first clinical trial 2020 Targeted commercial release of PURE EPTM System SYMBOL: BSGM 4 Market Opportunity � PURE EP TM Global EP Procedures Growing Rapidly Cardiac Ablation Procedures Are Key Hospital Revenue Drivers Complex Cardiac Ablation: 13.5% Growth Rate U.S. 3,425 EP labs OUS: 3,915 EP labs Total Global Addressable Market $2.0 Billion Published by Cardiovascular Rounds, Guggenheim Analyst � Chris Pasquale Data source: 2018 MD&D report Advisory Board and BioSig Technologies, Inc. estimates. SYMBOL: BSGM 5 EP During COVID-19 EP procedures are clinically urgent � Delaying procedure increases stroke risk and worsens outcomes EP procedures are revenue generating � CV surgery and invasive cardiology have the highest net annual revenue compared to all other service lines Median Revenues Per Case For Ablation and Select EP Procedures Inpatient Ablations $55,825 $23,240 DRG 273 (ablations w/MCC) $51,512 $19,460 DRG 274 (ablations w/o MCC) Outpatient Ablations $33,417 N/A APC 5213 (level 3 EP procedures) Inpatient CV Comparators $20,520 N/A All inpatient EP $9,600 N/A All inpatient CV Reimbursement rates continue to increase � From 2019 to 2020 ablations and LAAO (DRG 274) had a reimbursement rate increase of 8.8% CMS Reimbursement Changes From FY 2019 to FY 2020 Procedure Inpatient All inpatient services Ablations and LAAO (DRG 274) Pacemaker implant (DRG 244) ICD implant (DRG 227) Outpatient All outpatient services Ablations (APC 5213) Pacemaker implant (APC 5223) ICD implant (APC 5232) Reimbursement Rate Change 2.5% 8.8% 0.9% 0.9% 2.6% 6.3% 3.8% 5.3% *Data Source: Advisory Board, Published by Cardiovascular Rounds SYMBOL: BSGM 6 PURE EPTM System � Customer Installations Hospital of the University of Pennsylvania PURE EP TM Texas Cardiac Arrhythmia Institute SYMBOL: BSGM 7 Challenges in EP For All Procedures Physicians Can't Fix What They Can't See Signal Quality 81% of physicians rated signal quality as "Critical" Success Rate 20 - 40% of ablations are unsuccessful Data source: PUBMED 11/2017 and Healthwise and the University of Michigan, 12/15/2019. SYMBOL: BSGM 8 Expanded Product Adoption, Experience, and a Growing Database # PURE EP Procedures by Account TCAI (TX) 228 Mayo JAX (FL) 91 Penn (PA) 57 MGH (MA) 10 Deborah (NJ) 37 Overland Park (KS) 20 EE 1 cases (4 ctrs) 29 TOTAL 472 *Data as of Jan. 8, 2020 w a lag in some reporting *COVID shutdown Mar 12 - May 3 *Diagnosis was not logged for all procedures # Physician Users TCAI 11 Mayo 3 Penn 8 MGH 1 Deborah 2 Overland Park 2 Other EE Ctrs 5 TOTAL 32 Diagnosis Persistent AF Paroxysmal AF PVC Ischemic VT Nonischemic VT Diagnosis 14 Atypical Flutter 10 3 15 Atrial Tachycardia 7 0 57 AVNRT 7 17 Typical Flutter 8 11 AVRT/WPW 3 2019 1 center 69 procedures 2020 7 centers 425 procedures 2021 >20 centers >1000 procedures Our Recent PURE EPTM Study - ESC 2020 � A blinded, independent analysis confirmed that the PURE EPTM system's signals are preferred to conventional sources � In 35.5% of samples, the reviewers selected PURE EPTM data because "more signal components were visible" � PURE EPTM System produces reliable and high-quality signals when compared to the standard of care systems More clinical data is expected to be unblinded this year SYMBOL: BSGM 10 Physician Testimonies "The PURE EP System does provide innovative design with greater resolution and greater bandwidth, which should allow for safer and more efficacious ablations in the future." - K. Venkatachalam, M.D., Cardiac Electrophysiologist, Mayo Clinic "The quality of the recording that we can get in the lab can make a big difference [during the procedure]. . . The PURE EP System clearly gave us better quality of intracardiac recording [compared to conventional systems.]" - Andrea Natale, M.D., Texas Cardiac Arrhythmia Institute SYMBOL: BSGM 1 1 Commercialization � Regions and Centers of Excellence Overland Park Med. Ctr. Kansas City, KS Memorial Hospital South Bend, IN Mass. General Hospital Boston, MA Deborah Heart Center Browns Mills, NJ University of Pennsylvania Philadelphia, PA Texas Cardiac Arrhythmia Institute St David's Medical Center Austin, TX Mayo Clinic Jacksonville, FL Florida 120 EP Programs 240 Labs Texas 220 EP Programs 440 Labs Northeast 175 EP Programs 400 Labs Source: Industry data and BioSig Technologies, Inc. estimates. Revenue Potential $286 Million SYMBOL: BSGM 12 Business Model Data Sets Modules Service Agreements Data source: MarketWatch Global Electrophysiology Device Market Could Exceed $12.2 Billion By 2026 SYMBOL: BSGM 13 Value Drivers � Raised $41 million in 2020 � $32 million in cash on the balance sheet and no debt � Achieved first commercial contract 4Q20 � Expect to triple the customer base in 2021 � CE mark approval / EU entry Q4 2021 � Sequential revenue growth in 2021 : BSGM SYMBOL: BSGM 14 Management Team Kenneth L. Londoner, MBA Founder, Chairman, CEO, Director J & W Seligman & Co.; Endicott Management Partners Natasha Drapeau Executive Vice President IG Group Plc Todd Wiltshire Senior Vice President, Corporate Development Fidelity Investments John Kowalski Vice President, Sales Biosense Webster (Johnson & Johnson) Manasi Patwardhan Director of Strategic Planning Medtronic; Boston Scientific; Verily Life Sciences Steve Chaussy, CPA CFO Penske Automotive; Andy Ballou Vice President, Investor Relations Janney Montgomery Scott; RBC Capital Markets Barry Keenan, Ph.D, MBA, PMP Vice President, Engineering Medtronic; Alfred Mann Institute for Biomedical Engineering Julie Stephenson, BSN, MBA Vice President, Clinical Affairs Medtronic; Boston Scientific Olivier Chaudoir Senior Director, Marketing Biosense Webster, DePuy Synthes (Johnson & Johnson) SYMBOL: BSGM 15